Clinical trial
A Phase 2a Study to Evaluate the Safety and Efficacy of Namilumab in Subjects With Moderate-to-severely Active Axial Spondyloarthritis
NCT03622658 is registered in ClinicalTrials.gov with Izana Bioscience Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Study to Evaluate the Safety and Efficacy of Namilumab in Subjects With Moderate-to-severely Active Axial Spondyloarthritis
- Lead sponsor
- Izana Bioscience Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 6, 2018
- Completion date
- February 4, 2020
- Enrollment
- 42 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.